ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (ANIP) Revenue
Annual & quarterly revenue history · segment & region breakdown
ANIP · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsANI Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.92B, an increase of 43.78% year-over-year from $0.88B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.88B | +$0.27B | +43.78% |
| 2024-12-31 | $0.61B | +$0.13B | +26.20% |
| 2023-12-31 | $0.49B | +$0.17B | +53.87% |
| 2022-12-31 | $0.32B | +$0.10B | +46.38% |
| 2021-12-31 | $0.22B | +$0.01B | +3.67% |
| 2020-12-31 | $0.21B | +$0.00B | +0.93% |
| 2019-12-31 | $0.21B | +$0.00B | +2.47% |
| 2018-12-31 | $0.20B | +$0.02B | +13.99% |
| 2017-12-31 | $0.18B | +$0.05B | +37.49% |
| 2016-12-31 | $0.13B | +$0.05B | +68.53% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare ANIP revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ANI Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ANI Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ANI Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ANIP revenue · 4 questionsANIP's trailing twelve-month (TTM) revenue is $0.92B. That is an increase of 43.78% year-over-year from $0.88B in FY2025.
▸ Source: FMP · ANI Pharmaceuticals, Inc. SEC filings · GAAP · ANI Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026